Drug Profile


Latest Information Update: 06 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Antoxis
  • Class Flavonoids; Small molecules
  • Mechanism of Action Free radical modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Breast cancer; Cancer; Ovarian cancer

Highest Development Phases

  • Preclinical Breast cancer
  • Research Ovarian cancer

Most Recent Events

  • 06 Jul 2016 Oncamex is available for licensing as of 06 Jul 2016. http://www.antoxis.com/
  • 06 Jul 2016 Early research in Ovarian cancer in United Kingdom (unspecified route)
  • 01 Apr 2016 Preclinical trials in Breast cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top